. J Clin Endocrinol Metab. 2015 Jul;100(7):2784-2792. Epub 2015 May 8

Denosumab allows for supra-physiologic doses of calcitriol resulting in decreased parathyroid secretion and parathyroid hyperplasia. Supervised administration and weekly laboratory and clinical monitoring of serum calcium are recommended during the first month to prevent hypocalcemia

Autor: Chen CL, Chen NC, Liang HL, Hsu CY, Chou KJ, Fang HC, Lee PT

Leave a Reply

Tu dirección de correo electrónico no será publicada. Los campos obligatorios están marcados con *

  • 15 − Diez =